Squarepoint
EVFM

Squarepoint’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Squarepoint’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-751
Closed -$13K – 3701
2021
Q2 		$13K Buy
+751
New +$14.2K ﹤0.01% 3152
2021
Q1 		– Sell
-6,619
Closed -$239K – 3817
2020
Q4 		$239K Buy
6,619
+5,864
+777% +$212K ﹤0.01% 2387
2020
Q3 		$27K Sell
755
-8,724
-92% -$379K ﹤0.01% 2407
2020
Q2 		$402K Buy
9,479
+7,135
+304% +$481K 0.01% 1426
2020
Q1 		$187K Buy
+2,344
New +$188K ﹤0.01% 1495

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Squarepoint's EVFM Position: Q3 2021 in Review

Squarepoint sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 751 shares — an estimated $13K sold.

Squarepoint first reported a position in EVFM in Q1 2020 and held it in 5 quarters. The position peaked at $402K in Q2 2020. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

  • Squarepoint reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 751 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $13K.
  • Squarepoint first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Squarepoint's Evofem Biosciences, Inc. Common Stock position peaked at $402K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.